Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dysregulation of the mitosis-meiosis switch in testicular carcinoma in situ

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Endocytic collagen degradation: A novel mechanism involved in the protection against liver fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of HPV-related Anogenital Intraepithelial Neoplasia and Cancer in Men With Diabetes Compared With the General Population

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk of Anogenital Warts in Renal Transplant Recipients Compared with Immunocompetent Controls: A Cross-sectional Clinical Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

There is debate as to whether peritoneal implants associated with serous borderline tumours/atypical proliferative serous tumours (SBT/APSTs) of the ovary are derived from the primary ovarian tumour or arise independently in the peritoneum. We analysed 57 SBT/APSTs from 45 patients with advanced-stage disease identified from a nation-wide tumour registry in Denmark. Mutational analysis for hotspots in KRAS and BRAF was successful in 55 APSTs and demonstrated KRAS mutations in 34 (61.8%) and BRAF mutations in eight (14.5%). Mutational analysis was successful in 56 peritoneal implants and revealed KRAS mutations in 34 (60.7%) and BRAF mutations in seven (12.5%). Mutational analysis could not be performed in two primary tumours and in nine implants, either because DNA amplification failed or because there was insufficient tissue for mutational analysis. For these specimens we performed VE1 immunohistochemistry, which was shown to be a specific and sensitive surrogate marker for a V600E BRAF mutation. VE1 staining was positive in one of two APSTs and seven of nine implants. Thus, among 63 implants for which mutation status was known (either by direct mutational analysis or by VE1 immunohistochemistry), 34 (53.9%) had KRAS mutations and 14 (22%) had BRAF mutations, of which identical KRAS mutations were found in 34 (91%) of 37 SBT/APST-implant pairs and identical BRAF mutations in 14 (100%) of 14 SBT/APST-implant pairs. Wild-type KRAS and BRAF (at the loci investigated) were found in 11 (100%) of 11 SBT/APST-implant pairs. Overall concordance of KRAS and BRAF mutations was 95% in 59 of 62 SBT/APST-implant (non-invasive and invasive) pairs (p < 0.00001). This study provides cogent evidence that the vast majority of peritoneal implants, non-invasive and invasive, harbour the identical KRAS or BRAF mutations that are present in the associated SBT/APST, supporting the view that peritoneal implants are derived from the primary ovarian tumour.

Original languageEnglish
JournalThe Journal of pathology
Volume232
Issue number1
Pages (from-to)16-22
Number of pages7
ISSN0022-3417
DOIs
Publication statusPublished - Jan 2014

    Research areas

  • Cystadenocarcinoma, Serous, DNA Mutational Analysis, DNA, Neoplasm, Denmark, Female, Humans, Immunohistochemistry, Laser Capture Microdissection, Mutation, Ovarian Neoplasms, Peritoneal Neoplasms, Proto-Oncogene Proteins, Proto-Oncogene Proteins B-raf, Sensitivity and Specificity, Sequence Analysis, DNA, ras Proteins

ID: 44464439